Thursday 4 May | |
Apax Global Alpha Ltd | Q1 Results |
BAE Systems PLC | Trading Statement |
Cardiff Property PLC | Half Year Results |
Derwent London PLC | Trading Statement |
e-Therapeutics PLC | Full Year Results |
Glanbia PLC | Q1 Results |
IMI PLC | Trading Statement |
Mondi PLC | Trading Statement |
Morgan Sindall Group PLC | Trading Statement |
Next PLC | Trading Statement |
Rathbones Group PLC | Trading Statement |
Shell PLC | Q1 Results |
Spirent Communications PLC | Trading Statement |
Trainline PLC | Full Year Results |
Virgin Wines UK PLC | Half Year Results |
Wheaton Precious Metals | Q1 Results |
Friday 5 May | |
Eqtec PLC | Full Year Results |
InterContinental Hotels Group PLC | Trading Statement |
International Consolidated Airlines Group SA | Q1 Results |
Monday 8 May | |
no events scheduled | |
Tuesday 9 May | |
Kosmos Energy Ltd | Q1 Results |
Tialis Essential IT PLC | Full Year Results |
Treatt PLC | Half Year Results |
Wednesday 10 May | |
Anexo Group PLC | Full Year Results |
Asos PLC | Half Year Results |
Compass Group PLC | Half Year Results |
Directa Plus PLC | Full Year Results |
Georgia Capital PLC | Q1 Results |
MaxCyte Inc | Q1 Results |
Spirax-Sarco Engineering PLC | Trading Statement |
Valeura Energy Inc | Q1 Results |
Vertu Motors PLC | Full Year Results |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Inks strategic platform license agreement with Legend Biotech Corp, a firm focused in cell therapy. Under the terms of the agreement, Legend Biotech will get a non-exclusive worldwide license to use MaxCyte's Flow Electroporation technology and ExPERT platform in connection with the research, clinical development and commercialisation of cell-based therapeutical products. Accordingly, MaxCyte will be allowed to receive annual licensing fees and milestones from Legend during clinical development.
Read more